Given the increasing recognition of inflammatory and metabolic markers in HF progression, our results suggest that these novel ratios may offer additional clinical insights beyond traditional biomarkers such as NT-proBNP and albumin. The gene discussed is NPPB; the disease is hydrops fetalis.